
Zura Bio Limited: updates and filings
Price
$0.93
November 20, 2026Market cap $119M
What Ploutos Investor adds for Zura Bio
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 78% since Oct 27, 2026, when the 10-Q these figures come from was filed ($4.27 then, $0.93 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
October 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 9, 2026Other material eventsForm8-K
- Nov 3, 2026FilingFormEFFECT
- Oct 27, 2026Shelf registration for future offeringsFormS-3
- Oct 27, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 27, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Sep 30, 2026Shares registered for employeesFormS-8
- Aug 17, 2026Regulation FD disclosureForm8-K
- Aug 11, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 1, 2026Regulation FD disclosureForm8-K
- Jun 18, 2026Officer or director change, shareholder voteForm8-K
- May 22, 2026Additional annual meeting materialFormDEFA14A
- May 22, 2026Officer or director changeForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Results of operations, Regulation FD disclosureForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 23, 2026Officer or director changeForm8-K
- Mar 19, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 19, 2026Results of operations, Regulation FD disclosureForm8-K
- Mar 10, 2026Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 9, 2026 | 8-K | Other material events | Document |
| Nov 3, 2026 | EFFECT | Filing | Document |
| Oct 27, 2026 | S-3 | Shelf registration for future offerings | Document |
| Oct 27, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 27, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Sep 30, 2026 | S-8 | Shares registered for employees | Document |
| Aug 17, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 11, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 1, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 18, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 22, 2026 | 8-K | Officer or director change | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 23, 2026 | 8-K | Officer or director change | Document |
| Mar 19, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 19, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Mar 10, 2026 | 8-K | Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 8, 2021.
The full analysis
What do Zura Bio's filings show?
The filings are where every one of Zura Bio's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.